CRISPR Therapeutics to present Phase 1b trial data on gene editing therapy for severe hypertriglyceridemia at AHA 2026.

CRISPR Therapeutics announced it will present clinical data from its Phase 1b trial of CTX310, a CRISPR/Cas9 gene editing therapy targeting ANGPTL3 for severe hypertriglyceridemia, at the American Heart Association Scientific Sessions 2026. This late-breaking oral presentation will occur on November 9, 2026. The data could mark progress in treating cardiovascular diseases using gene editing. CRISPR Therapeutics continues to develop multiple in vivo liver gene editing programs for cardiovascular and other serious diseases.

CRISPR Therapeutics has a market capitalization of $5.06 billion as of October 8, 2026, 19:42 WIB, indicating significant investor interest in its gene editing programs. The stock price on Pluang is USD 51.26, down 2.08% for the day, while trading volume is robust at 1,678,371 shares. This activity comes as the company prepares to present important clinical data at the American Heart Association Scientific Sessions 2026.